{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-chronic/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 1bdaac06-5f57-47a7-baab-a39592c74b8f --><h2>Trimethoprim</h2><!-- end field 1bdaac06-5f57-47a7-baab-a39592c74b8f -->","summary":"","htmlStringContent":"<!-- begin item 8987aad7-3d0d-4963-b6fe-08949f0f3301 --><!-- end item 8987aad7-3d0d-4963-b6fe-08949f0f3301 -->","topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","lastRevised":"Last revised in September 2019","chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","fullItemName":"Management","slug":"management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ce130012-76c4-5651-8763-653f96b9dcda","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 15fee111-31df-4bbb-8be1-bd4181e9f9c0 --><h3>Contraindications</h3><!-- end field 15fee111-31df-4bbb-8be1-bd4181e9f9c0 -->","summary":"","htmlStringContent":"<!-- begin item e1f84dcd-5e5f-4d4a-a5fe-9f0f0bc16a34 --><!-- begin field 5b4792a2-2194-418b-b11b-4341c26a14e4 --><ul><li>Avoid using trimethoprim in people with blood dyscrasias.<ul><li>Because of its potential anti-folate effect, there have been reports that trimethoprim causes blood disorders. Consequently, trimethoprim is contraindicated in anyone with blood dyscrasias.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013a</a>]</p><!-- end field 5b4792a2-2194-418b-b11b-4341c26a14e4 --><!-- end item e1f84dcd-5e5f-4d4a-a5fe-9f0f0bc16a34 -->","subChapters":[]},{"id":"044f5577-ecfd-5511-86a1-eb01dae10ec9","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 52e430c8-b333-44fa-a75f-83d044a4a54b --><h3>Cautions</h3><!-- end field 52e430c8-b333-44fa-a75f-83d044a4a54b -->","summary":"","htmlStringContent":"<!-- begin item 307a1e42-10cc-4729-8ded-d60b3fd075c4 --><!-- begin field d293a838-fa4c-4eb0-b07d-49453e5fbcdb --><p><strong>Trimethoprim should be prescribed with caution in the following conditions:</strong></p><ul><li><strong>Renal impairment</strong><ul><li>As the drug is predominantly excreted by the kidney, dose adjustment may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">BNF 68, 2014</a>]:<ul><li>If estimated glomerular filtration rate (eGFR) is 15–30 mL/minute/1.73 m<sup>2</sup>, use half the normal dose after 3 days.</li><li>If eGFR is less than 15 mL/minute/1.73 m<sup>2</sup>, use half the normal dose.</li><li>If eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, monitor the plasma trimethoprim concentration.</li></ul></li></ul></li><li><strong>Folate deficiency</strong><ul><li>Because of its potential anti-folate effect, there is a risk of further exacerbating folate deficiency in people who are already folate deficient or who are predisposed to folate deficiency (for example elderly people). Consequently, consider prescribing a folate supplement (if this has not already been prescribed) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013a</a>].</li></ul></li></ul><!-- end field d293a838-fa4c-4eb0-b07d-49453e5fbcdb --><!-- end item 307a1e42-10cc-4729-8ded-d60b3fd075c4 -->","subChapters":[]},{"id":"e0f60e17-587f-5204-988f-0dc77a75d0db","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field acad9502-a906-4178-b657-347f9eda1d0d --><h3>Adverse effects</h3><!-- end field acad9502-a906-4178-b657-347f9eda1d0d -->","summary":"","htmlStringContent":"<!-- begin item 7ae07905-60d9-407f-b282-4ae2c43e2899 --><!-- begin field fd2955dd-770e-4107-974a-44a51e81e3f4 --><ul><li>Trimethoprim is generally well tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013a</a>]:<ul><li>Nausea, vomiting, pruritus, and skin rashes have occasionally been reported. These are generally mild and reversible when trimethoprim is withdrawn.</li><li>Severe adverse drug reactions with trimethoprim are rare.</li></ul></li><li>There have been rare reports of trimethoprim causing haematological adverse effects, including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Aronson, 2006</a>]:<ul><li>Macrocytic and megaloblastic anaemia: this is more likely in people with pre-existing folate deficiency.</li><li>Agranulocytosis — very rare. In people where leukocytes are monitored regularly, mild leukopenia has been reported in 0.4–10% of people taking trimethoprim or co-trimoxazole (trimethoprim plus sulfamethoxazole).</li><li>Aplastic anaemia, neutropenia, thrombocytopenia, and pancytopenia.</li></ul></li><li>For people receiving long-term trimethoprim treatment, the British National Formulary advises that they should be warned to seek immediate medical attention if they develop signs of blood disorders such as fever, sore throat, rash, mouth ulcers, purpura, bruising, or bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">BNF 68, 2014</a>].</li></ul><!-- end field fd2955dd-770e-4107-974a-44a51e81e3f4 --><!-- end item 7ae07905-60d9-407f-b282-4ae2c43e2899 -->","subChapters":[]},{"id":"e6b1e608-d36d-5ad0-917c-e444cb4254a7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 68a767a6-348c-4c9d-9e96-bef276dcd0df --><h3>Drug interactions</h3><!-- end field 68a767a6-348c-4c9d-9e96-bef276dcd0df -->","summary":"","htmlStringContent":"<!-- begin item 40e6d1bf-eb7c-496c-b1ff-c5eb13960a42 --><!-- begin field c3447b0f-d428-4934-9ac2-448efa9e8a56 --><ul><li>Drug interactions associated with trimethoprim include:<ul><li><strong>Methotrexate (a folate antagonist) </strong>— several cases of bone marrow suppression have been reported (some fatal) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Baxter and Preston, 2013</a>].</li><li><strong>Azathioprine </strong>— increased risk of haematological toxicity has been reported in some people with a renal transplant who are taking azathioprine — particularly if both drugs are given over a prolonged period [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Baxter and Preston, 2013</a>].<ul><li>Nevertheless, for most people, both drugs can be taken together. The combination is commonly used in practice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Baxter and Preston, 2013</a>].</li><li>The reaction is also expected for mercaptopurine (a metabolite of azathioprine) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Baxter and Preston, 2013</a>].</li></ul></li><li><strong>Phenytoin and fosphenytoin (a pro-drug of phenytoin) </strong>— there is a small risk of phenytoin toxicity (particularly if the serum phenytoin levels are at the top end of the range) as trimethoprim can decrease the clearance of phenytoin. Signs of phenytoin toxicity include blurred vision, nystagmus, ataxia, or drowsiness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Baxter and Preston, 2013</a>].</li><li><strong>Ciclosporin </strong>— increased nephrotoxicity has been reported [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013a</a>].</li><li><strong>Digoxin </strong>— trimethoprim has been reported to increase digoxin levels by an average of 22% in nine elderly people after taking trimethoprim 200 mg daily for 14 days (although an increase of 75% was experienced by one person).</li><li><strong>Warfarin </strong>— the manufacturer of trimethoprim warns that it may potentiate the anticoagulant effect of warfarin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">ABPI Medicines Compendium, 2013a</a>].</li></ul></li></ul><!-- end field c3447b0f-d428-4934-9ac2-448efa9e8a56 --><!-- end item 40e6d1bf-eb7c-496c-b1ff-c5eb13960a42 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}